|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.94 CAD | +10.36% |
|
+17.61% | +35.86% |
| 05-17 | XORTX Therapeutics Reprices Warrants Connected With U.S. IPO | MT |
| 05-17 | XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO | MT |
XORTX Therapeutics Inc. announced that the appointment of James Fairbairn as Interim Chief Financial Officer. James Fairbairn was the Company’s Chief Financial Officer from November 2018 through July 2021. He has more than 20 years of experience with publicly-traded companies.
He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and an Institute-certified Director. Jim Fairbairn holds a B.A. from the University of Western Ontario.
| 1st Jan change | Capi. | |
|---|---|---|
| +35.86% | 7.57M | |
| +10.52% | 115B | |
| +12.17% | 106B | |
| -5.85% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.56% | 17.56B | |
| -40.50% | 17.32B | |
| +6.46% | 14.03B | |
| +30.42% | 12.13B |
XORTX THERAPEUTICS INC. 
